## EW: Edwards Lifesciences Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.4% below STRENGTH zone (4.0-10.0%); PEG 4.78 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (48% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($83.03)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Edwards wins FDA nod for Sapien M3 mitral valve, marking first transseptal transcatheter therapy**
- Source: MassDevice | 20251223T143440 | Bullish | Relevance: 100%
- Edwards Lifesciences has received FDA approval for its Sapien M3 mitral valve replacement system, the first transcatheter mitral regurgitation therapy to use a transseptal approach. This approval came ahead of schedule and allows the device to treat patients with symptomatic moderate-to-severe or severe MR who are unsuitable for surgery or TEER therapy. The Sapien M3 system, which builds on the proven Sapien platform, also treats symptomatic mitral valve dysfunction associated with mitral annular calcification.

**2. New catheter-based heart valve offers option for patients unfit for surgery**
- Source: Stock Titan | 20251223T140159 | Bullish | Relevance: 100%
- Edwards Lifesciences has received FDA approval for its SAPIEN M3 mitral valve replacement system, marking it as the first transcatheter therapy utilizing a transseptal approach for mitral regurgitation. This system provides a new treatment option for patients deemed unsuitable for traditional surgery or other repair therapies. The SAPIEN M3 offers a fully percutaneous mitral valve replacement, which has shown significant elimination of mitral regurgitation and improved patient symptoms and quality of life in clinical trials.

**3. Edwards Lifesciences Corporation $EW Shares Sold by OLD National Bancorp IN**
- Source: MarketBeat | 20251224T110801 | Somewhat-Bullish | Relevance: 100%
- OLD National Bancorp IN significantly reduced its stake in Edwards Lifesciences (NYSE:EW) by 69.4% in Q3, selling 132,226 shares and retaining 58,421 shares valued at $4.543 million. Despite this, Wall Street analysts maintain a "Moderate Buy" consensus for EW, with an average price target of $93.95, following multiple rating upgrades. Institutional investors collectively hold about 79.46% of the company's stock, though some insiders have recently decreased their holdings.

**4. Edwards lands first FDA approval for transcatheter MVR**
- Source: BioWorld MedTech | 20251223T230850 | Bullish | Relevance: 100%
- Edwards Lifesciences Corp. has received U.S. FDA approval for its Sapien M3 mitral valve replacement system, marking the first transcatheter therapy using a transseptal approach for mitral regurgitation. The system is indicated for patients with symptomatic moderate-to-severe or severe MR, or mitral valve dysfunction, who are deemed unsuitable for surgery or TEER. This approval represents a significant advancement in the treatment options for these patients.

**5. Edwards Lifesciencesâ€™ SAPIEN M3 becomes first FDA-approved mitral valve system**
- Source: Investing.com | 20251223T142340 | Bullish | Relevance: 100%
- Edwards Lifesciences has received FDA approval for its SAPIEN M3 mitral valve replacement system, the first transcatheter therapy using a transseptal approach for mitral regurgitation. This approval covers patients unsuitable for surgery or transcatheter edge-to-edge repair and those with mitral valve dysfunction associated with mitral annular calcification. The company is trading near its 52-week high, reflecting investor optimism, and analysts have recently upgraded its stock ratings.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 11, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | JP Morgan | $100 | $90 | +11% |
| 2025-12-17 | Canaccord Genui | $87 | $89 | -2% |
| 2025-12-16 | Baird | $87 | $88 | -1% |
| 2025-12-11 | Citigroup | $101 | $96 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | JP Morgan | up | Overweight |
| 2025-12-17 | Canaccord Genui | main | Hold |
| 2025-12-16 | Baird | main | Neutral |
| 2025-12-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 12 ($3.78M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.5%)
- Blackrock Inc.: 9.4% (-2.4%)
- JPMORGAN CHASE & CO: 8.6% (+87.2%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.6% (+4.9%)

### Key Risks

1. Insider selling cluster: $3.8M in recent transactions.
2. Valuation stretched: PEG 4.8x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 11 raises (avg +5%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.78 signals overvaluation risk, limited margin of safety. Forward P/E 30.1x stretched relative to 11% growth. Quality metrics strong (margin 23%). Balance sheet: strong liquidity (4.0x), low leverage (D/E 0.30). Insider selling cluster ($3.8M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $50.7B |
| Beta | 0.97 |
| 52W Range | $65.94 - $87.89 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.78 |
| Forward P/E | 30.1 |
| Current P/E | 33.4 |
| YoY Growth | 11.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 0.4% (minimal 5-day change). Below STRENGTH zone by 3.6pp (needs >4.0% for momentum thesis). MRS_5 (-0.5%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. Volume at 48% of 20MA suggests lack of conviction. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.40% (CS: 59) | Neutral |
| RSI_14 | 58.5 | Neutral |
| MACD Histogram | 0.07 | Bullish |
| vs SMA20 | 1.015x | Above |
| vs SMA50 | 1.040x | Above |
| vs SMA200 | 1.113x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $86.35
- **Stop Loss:** $83.03 (3.8% risk)
- **Target:** $89.67 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 361
- **Position Value:** $31,172.35
- **Portfolio %:** 31.17%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-02-11 (Est: $0.62)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.59 | $0.67 | +12.6% |
| 2025Q2 | $0.62 | $0.67 | +7.6% |
| 2025Q1 | $0.60 | $0.64 | +7.5% |
| 2024Q4 | $0.55 | $0.59 | +6.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*